Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
grade A 143.76 1.82% 2.57
BGNE closed up 1.82 percent on Friday, August 16, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical BGNE trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Inside Day Range Contraction 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Reached Overbought Strength 1.82%

Older signals for BGNE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Biopharmaceutical Cancers Monoclonal Antibodies Oncogenes Humanized Antibody Lymphomas Ras Subfamily Braf Kras
Is BGNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 182.305
52 Week Low 105.19
Average Volume 251,463
200-Day Moving Average 131.0866
50-Day Moving Average 127.861
20-Day Moving Average 134.456
10-Day Moving Average 135.419
Average True Range 5.1189
ADX 21.82
+DI 26.791
-DI 10.1037
Chandelier Exit (Long, 3 ATRs ) 129.9659
Chandelier Exit (Short, 3 ATRs ) 133.8567
Upper Bollinger Band 142.7868
Lower Bollinger Band 126.1252
Percent B (%b) 1.06
BandWidth 12.391861
MACD Line 3.4527
MACD Signal Line 2.6929
MACD Histogram 0.7598
Fundamentals Value
Market Cap 5.73 Billion
Num Shares 39.8 Million
EPS -4.97
Price-to-Earnings (P/E) Ratio -28.93
Price-to-Sales 0.00
Price-to-Book 12.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 151.31
Resistance 3 (R3) 150.72 147.63 150.05
Resistance 2 (R2) 147.63 145.71 147.92 149.63
Resistance 1 (R1) 145.69 144.52 146.66 146.28 149.21
Pivot Point 142.60 142.60 143.08 142.89 142.60
Support 1 (S1) 140.66 140.68 141.63 141.25 138.31
Support 2 (S2) 137.57 139.49 137.86 137.89
Support 3 (S3) 135.63 137.57 137.47
Support 4 (S4) 136.22